Nortrel Oral Contraceptive Tablets Recalled for Discolored Inert Remainder Tablets
Teva Pharmaceuticals is recalling 12,916 cartons of Nortrel oral contraceptive tablets nationwide due to discolored inert remainder tablets that may cause confusion. Affected lot: #100042978, expiration 7/31/2024.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: FDA Class III recall with no reported illnesses or injuries. The hazard is purely cosmetic discoloration of inert remainder tablets. Per the severity rubric, FDA Class III recalls are typically scored 1–2, and cosmetic defects score 1.
Plain-English summary
Teva Pharmaceuticals USA, Inc. is recalling 12,916 cartons of Nortrel (norethindrone and ethinyl estradiol) 0.5/35 mg tablets nationwide. The affected lot is #100042978 with an expiration date of July 31, 2024. Each carton contains three blister cards with 28 tablets per card. The recalled cartons contain discolored tablets in shades of blue mixed in with the white inert remainder tablets.
The inert remainder tablets serve as a visual marker to help patients maintain proper medication sequencing. Discolored inert tablets may cause confusion about which tablets are active versus inactive when taking their medication.
Patients currently taking Nortrel should check their blister pack for the affected lot number and expiration date. Patients should contact their pharmacist or healthcare provider if they have questions about whether their medication is part of the recall. Patients should continue taking their medication as prescribed.
The recalled product
- Product
- NORTREL (NORETHINDRONE AND ETHINYL ESTRADIOL)
- Brand
- NORTREL
- Manufacturer
- Teva Pharmaceuticals USA, Inc
- Category
- Drug — Oral Contraceptive
- Hazard
- Affected units
- 12,916
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 100042978
- Exp 7/31/2024
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Teva Pharmaceuticals USA, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Teva Pharmaceuticals USA, Inc
See all →- SevereTeva Recalls Trazodone Hydrochloride Tablets Due to Foreign Material
FDA (Drugs) · 2026-09-09
- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- ModerateTeva clonidine 0.3 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
Same hazard · discoloration
See all →- ModerateFresenius NaturaLyte Liquid Acid Concentrate Recalled for Discoloration
FDA (Devices) · 2026-09-09
- ModerateFresenius Citrasate Liquid Acid Concentrate Recalled for Discoloration
FDA (Devices) · 2026-09-09
- ModerateShilpa Medicare Recalls Discolored PEMRYDI RTU Injection Vials
FDA (Drugs) · 2026-08-26
- SevereShilpa Medicare Recalls Discolored Pemetrexed Injection Vials
FDA (Drugs) · 2026-08-26
- ModeratePantoprazole Sodium Tablets Recalled for Discoloration Issues
FDA (Drugs) · 2026-04-29